Kirkland Advises Thoma Bravo on Controlling Investment in Bluesight
Kirkland & Ellis counseled Thoma Bravo, a leading software investment firm, on its strategic controlling investment in Bluesight, the Medication Intelligence™ Company. Current investor New Leaf Ventures will remain invested in Bluesight’s business. Financial terms of the transaction were not disclosed.
Read Thoma Bravo’s press release
The Kirkland team was led by corporate partners John Kaercher and Andrew Walker and associates Oscar Leija and Mike Fiedorowicz with assistance from corporate partner Bradley Reed; debt finance partner Fred Lim and associates David Love and Tina He; tax partners Adam Kool and Kevin Coenen and associate Natalie Kannan; technology & intellectual property transactions partners Aaron Lorber and Kevin Jacobsen; executive compensation partner Jake Ebers and associate Tom Kotlowski; employee benefits partner Robert Zitko and associate Nate Linger; employment & labor partner Sydney Jones and associate Jaime Wamble; and healthcare partner Anthony Del Rio and associate Olivia Seraphim.
Related: Kirkland Counsels Thoma Bravo on Bluesight’s Acquisition of Medacist
